Overview
McDermott Will & Emery has advised the Nov Santé Actions Non Cotées fund, managed by Eurazeo and launched at the initiative of France Assureurs and Caisse des Dépôts, on its third growth equity investment in Germitec, a French MedTech innovator in high-level disinfection of ultrasound probes.
This EUR 29 million Series B investment was made alongside the company’s historical shareholders, including Kurma Partners (Eurazeo’s Venture Santé subsidiary), Financière Arbevel, Turenne Capital and the founding family.
The McDermott team involved in this transaction was composed of:
Corporate
Fabrice Piollet, Partner
Marie Mouly and Jordan Ohayon, Associates
Ruben Johannsen, Juriste
Life Sciences
Anne-France Moreau, Partner
Alice Villagrasa, Associate
Employment
Naré Arshakyan, Associate
IP/IT
Charles de Raignac, Counsel
Julie Favreau, Associate
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
